Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis (CanAct)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00649545
Expanded Access Status : Approved for marketing
First Posted : April 1, 2008
Last Update Posted : April 1, 2008
Sponsor:
Information provided by:
Abbott

Tracking Information
First Submitted Date March 27, 2008
First Posted Date April 1, 2008
Last Update Posted Date April 1, 2008
 
Descriptive Information
Brief Title Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis
Brief Summary The primary objective of this study is to assess the safety (by collecting adverse events and serious adverse events) of adalimumab administered every other week to patients with moderately to severly active rheumatoid arthritis who have failed prior disease-modifying anti-rheumatic drugs (DMARDs).
Detailed Description Not Provided
Study Type Expanded Access
Intervention Biological: adalimumab
40 mg every other week
Other Names:
  • ABT-D2E7
  • Humira
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Approved for marketing
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT00649545
Responsible Party Larry McNamee, Sr. clinical Research Manager, Abbott
Study Sponsor Abbott
Collaborators Not Provided
Investigators Not Provided
PRS Account Abbott
Verification Date March 2008